Scinai Immunotherapeutics (SCNI) News
NASDAQ: SCNIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
1.58+0.0258 (+1.66%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SCNI news summary
We found 2 recent headlines mentioning Scinai Immunotherapeutics (SCNI): 0 in the past week and 1 in the past 30 days, most often from PR Newswire. For price context, SCNI is up 1.66% at $1.58. The most recent story, "Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands", was published by PR Newswire on Nov 5, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Scinai Immunotherapeutics headlines
- Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business ExpandsOctober agreement advances the U.S. customer program to approximately $5.1 million in committed base services JERUSALEM, Nov. 5, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)…PR Newswire
- Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant InducementJERUSALEM, Oct. 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and…PR Newswire